VOLKER FISCHER, LAURIE JOHANSON, FRANCIS HEITZ, ROBERT TULLMAN, ELIZABETH GRAHAM, JEAN-PIERRE BALDECK AND WILLIAM T. ROBINSON
|
|
- Wesley Lewis
- 5 years ago
- Views:
Transcription
1 /99/ $02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 3 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. THE 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR FLUVASTATIN: EFFECT ON HUMAN CYTOCHROME P-450 AND IMPLICATIONS FOR METABOLIC DRUG INTERACTIONS VOLKER FISCHER, LAURIE JOHANSON, FRANCIS HEITZ, ROBERT TULLMAN, ELIZABETH GRAHAM, JEAN-PIERRE BALDECK AND WILLIAM T. ROBINSON Drug Metabolism and Pharmacokinetics, Novartis Institute for Biomedical Research, East Hanover, New Jersey (Received August 20, 1998; accepted November 16, 1998) This paper is available online at ABSTRACT: Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, was metabolized by human liver microsomes to 5-hydroxy-, 6-hydroxy-, and -fluvastatin. Total metabolite formation was biphasic with apparent K m values of 0.2 to 0.7 and 7.9 to 50 M and intrinsic metabolic clearance rates of 1.4 to 4 and 0.3 to 1.5 ml/h/mg microsomal protein for the high and low K m components, respectively. Several enzymes, but mainly CYP2C9, catalyzed fluvastatin metabolism. Only CYP2C9 inhibitors such as sulfaphenazole inhibited the formation of both 6-hydroxy- and N- deisopropyl-fluvastatin. 5-Hydroxy-fluvastatin formation was reduced by compounds that are inhibitors of CYP2C9, CYP3A, or CYP2C8. Fluvastatin in turn inhibited CYP2C9-catalyzed tolbutamide and diclofenac hydroxylation with K i values of 0.3 and 0.5 M, respectively. For CYP2C8-catalyzed 6 -hydroxy-paclitaxel formation the was 20 M and for CYP1A2, CYP2C19, and 1 Abbreviations used are: HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; CYP or P-450, cytochrome P-450; LC/MS, liquid chromatography/mass spectrometry. Send reprint requests to: Dr. Volker Fischer, Novartis Institute for Biomedical Research, 59 Route 10, East Hanover, New Jersey volker. fischer@pharma.novartis.com 410 CYP3A catalyzed reactions, no could be determined up to 100 M fluvastatin. All three fluvastatin metabolites were also formed by recombinant CYP2C9, whereas CYP1A1, CYP2C8, CYP2D6, and CYP3A4 produced only 5-hydroxy-fluvastatin. K m values were 1, 2.8, and 7.1 M for CYP2C9, CYP2C8, and CYP3A, respectively. No difference in fluvastatin metabolism was found between the CYP2C9 R144 and CYP2C9 C144 alleles, suggesting the absence of polymorphic fluvastatin metabolism by these alleles. CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2E1, and CYP3A5 did not produce detectable amounts of any metabolite. This data indicates that several human cytochrome P-450 enzymes metabolize fluvastatin with CYP2C9 contributing 50 80%. Any coadministered drug would therefore only partially reduce the metabolic clearance of fluvastatin; therefore, the likelihood for serious metabolic drug interactions is expected to be minimal. Fluvastatin (Lescol) is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 1 reductase inhibitor which consistently lowers low density lipoprotein cholesterol levels by 20 to 30% at a daily dose of 20 to 40 mg (Levy et al., 1993; Peters et al., 1993; Davidson, 1994). Like most HMG-CoA reductase inhibitors, fluvastatin has a low incidence rate ( 0.5%) of musculoskeletal side effects such as myopathy and rhabdomyolysis. These side effects, however, increase for certain HMG-CoA reductase inhibitors with increased systemic concentrations of the HMG-CoA reductase inhibitors when coadministered with other drugs. Lovastatin plasma exposure (area under the plasma concentration time curve), for example, increases 20-fold when coadministered with cyclosporine A (Olbricht et al., 1997) and the incidence of musculoskeletal side effects increases up to 28% (Tobert, 1988). In combination with itraconazole, lovastatin concentrations increase 10-fold (Kantola et al., 1997); this combination has been associated with rhabdomyolysis (Lees and Lees, 1995). Most of these interactions have been attributed to the inhibition of CYP3A, which is the major enzyme metabolizing most HMG-CoA reductase inhibitors including lovastatin, simvastatin, atorvastatin, and cerivastatin (Wang et al., 1991; Prueksaritanont et al., 1997; Boberg et al., 1997; Physicians Desk Reference, 1998). Additional factors besides metabolism may also contribute to the observed drug interactions. For example, lovastatin has recently been shown to be a substrate for P-glycoprotein (Dimitroulakos and Yeger, 1996) and increased lovastatin concentrations could in part be due to a decrease of biliary clearance after P-glycoprotein inhibition. A similar mechanism might also explain increased (5 23-fold) plasma concentrations of pravastatin in the presence of cyclosporine A (Regazzi et al., 1993), because pravastatin is thought not to be metabolized by CYP3A. For fluvastatin, relatively few cases of musculoskeletal side effects have been reported, even when administered in combination with other drugs (Peters et al., 1993; Peters, 1996; Plosker and Wagstaff, 1996). This may be attributed to its favorable biopharmaceutical profile. Fluvastatin is completely absorbed from the intestinal tract. Systemic exposure, however, is limited due to first-pass metabolism with maximal plasma concentrations of 0.35 M after a 40-mg (0.1-mMol) oral dose. Fluvastatin is almost exclusively eliminated via metabolism, mainly hydroxylation, at the 5- and 6-position of the indole moiety and ation. Only the hydroxylated metabolites retain some HMG-CoA reductase inhibitory activity, yet they
2 FLUVASTATIN METABOLISM AND DRUG INTERACTIONS 411 are not found in the systemic circulation (Tse et al., 1992; Dain et al., 1993). Based on these pharmacokinetic characteristics, transport proteins such as P-glycoprotein should not be involved in the disposition of fluvastatin. Drug interactions affecting fluvastatin disposition should therefore be limited to metabolic interactions. However, although fluvastatin has been reported to inhibit CYP3A competitively at high (200 M) concentrations (Ikeda et al., 1997), CYP3A does not appear to be the major enzyme eliminating fluvastatin. CYP3A inhibitors do not affect fluvastatin to the same extent as the other HMG-CoA reductase inhibitors. Fluvastatin area under the plasma concentration time curve has been increased only 1.9-fold in the presence of cyclosporine A (Goldberg and Roth, 1996) and fluvastatin plasma concentrations have been unchanged when given together with itraconazole (Kantola et al., 1997). At much lower concentrations ( 0.2 M), fluvastatin has been reported to also competitively inhibit CYP2C9 (Transon et al., 1996). The objective of this study was to further define the enzymes involved in fluvastatin elimination using in vitro techniques. Furthermore, the reciprocal effects on the biotransformation of fluvastatin and potentially coadministered drugs were assessed to provide guidance for clinical use. Materials and Methods Chemicals. [ 14 C]Fluvastatin (2 GBq/mmol) (R*, S*-( )-7-[3-(4-fluorophenyl)-1-(methylethyl)-[3-14 C] 1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid monosodium salt) was obtained from Novartis Pharmaceuticals Corporation (East Hanover, NJ). The purity of the labeled fluvastatin was 94.5% by HPLC. [ 3 H]Glibenclamide (1.35 GBq/mmol, cyclohexol-3,3-3 H) was obtained from DuPont-NEN (Boston, MA). [ 14 C]Paclitaxel (2.3 GBq/mmol, 2-benzoyl ring- UL- 14 C) and [ 14 C]phenacetin (0.5 GBq/mmol, phenacetin-ring-ul- 14 C) were obtained from Sigma (St. Louis, MO). [ 14 C]Tolbutamide (2 GBq/mmol), [ 14 C]S-mephenytoin (2.2 GBq/mmol), and [ 3 H]cyclosporine A (296 GBq/ mmol) were obtained from Amersham (Little Chalfont, UK). Unlabeled diclofenac, 4 -hydroxy-diclofenac, valsartan, cyclosporine A, isradipine, and fluvastatin metabolites (5-hydroxy-, 6-hydroxy- and N- deisopropyl- fluvastatin) were obtained from Novartis. Janssen Biotech NV (Olen, Belgium) provided itraconazole. Furafylline and ketoconazole were purchased from Ultrafine Chemicals (Manchester, UK). Chlorzoxazone, chlorpropamide, sulfaphenazole, quinidine, erythromycin, sulfinpyrazone, ethinyl estradiol, glyburide, troleandomycin, nifedipine, dextromethorphan, phenacetin, clofibrate, paclitaxel, sparteine, and tolbutamide were purchased from Sigma. Glibornuride and mibefradil were a gift from Hoffman-La Roche (Basel, Switzerland), lovastatin was obtained from Merck (West Point, PA), and pravastatin from Bristol-Myers Squibb (Princeton, NJ). All other reagents were obtained from commercial sources and were of the highest quality available. Biologicals. Human liver tissue which could not be used for transplantation was obtained as either pieces or microsomes from the International Institute for the Advancement of Medicine (Exton, PA), GGM-002; from Vitron Inc. (Tucson, AZ), HL44, HL45, HL46; and from the Novartis liver bank, M8 (Ball et al., 1992). Microsomes from livers GGM-002 and M8 were prepared in house by differential centrifugation as described previously (Ball et al., 1992). Microsomal protein was determined by the Bradford method (Bradford, 1976) and the cytochrome P-450 (P-450) content was determined from the carbon monoxide spectra according to the method of Omura and Sato (1964). Total P-450 content was 0.44, 0.23, 0.26, 0.36, and 0.29 nmol P-450/mg for microsomal GGM-002, HL44, HL45, HL46, and M8, respectively. Human lymphoblast-expressed human CYP1A1 (53 pmol P-450/mg protein), CYP1A2 (140 pmol P-450/mg protein), CYP2A6 (140 pmol P-450/mg protein), CYP2B6 (86 pmol P-450/mg protein), CYP2C8 (28 pmol P-450/mg protein), CYP2C9 C144 (15 pmol P-450/mg protein), CYP2C9 R144 (47 pmol P-450/mg protein), CYP2C19 (14 pmol P-450/mg protein), CYP2D6 (42 pmol P-450/mg protein), CYP2E1 (150 pmol P-450/mg protein), CYP3A4 (65 pmol P-450/mg protein), and baculovirusexpressed human CYP2C8 (370 pmol P-450/mg protein), CYP2C9 R144 (500 pmol P-450/mg protein), CYP2C9 C144 (480 pmol P-450/mg protein), and CYP3A4 (230 pmol P-450/mg protein) were purchased from Gentest Corp. (Woburn, MA). Metabolism. Fluvastatin, diclofenac, and glibornuride were incubated with human liver microsomes in a final volume of 500 l of 0.1 M phosphate buffer at ph 7.4 in the absence or presence of different inhibitors. Substrate and inhibitor (0 100 M) were added in dimethyl sulfoxide not to exceed 1% v/v. Metabolism was initiated by the addition of 0.2 mm -NADPH and the NADPH regenerating system to give final concentrations of 1 mm NADP,5 mm isocitrate, 5 mm MgCl 2, and 1 U isocitrate dehydrogenase. For fluvastatin, the reactions were stopped with half the volume of cold methanol and for diclofenac with 125 l of cold acetonitrile. Typical incubation conditions such as substrate concentration, incubation time, and microsomal protein content were as follows: fluvastatin ( M, min, 200 g), diclofenac (5 100 M, 10 min, 100 g), and glibornuride ( mm, 40 min, 500 g). Human liver microsomal incubations with all other substrates were performed essentially as described previously (Fischer et al., 1998). For fluvastatin (50 M) incubations with lymphoblast-expressed human P-450 (1 mg), the incubation time was 60 min. HPLC Analysis. The incubation media was separated from the denatured protein by centrifugation at 40,000g for 15 min using an Avanti centrifuge (Beckman Instruments, Palo Alto, CA). The pellets of the glyburide and glibornuride samples were then extracted once with 100 l of methanol, and the extract was combined with the primary supernatant. Aliquots of the supernatant were directly analyzed by HPLC on either a HP1090 (Hewlett Packard, Waldbronn, Germany) or an Alliance (Waters, Milford, MA) system. Fluvastatin and its metabolites were separated by gradient HPLC (LC 18-DB, 5- m particle size, mm and mm; Supelco Inc., Bellefonte, PA) with 10 mm ammonium acetate (ph 7.4) and methanol at a total flow of 1 ml/min at 50 C. Methanol was held constant at 0% for 3 min and then increased linearly to reach 35% at 33 min and then to 100% at 80 min. Glibornuride was chromatographed at 40 C (LC 18, 5- m particle size, mm and mm; Brownlee, San Jose, CA) at a total flow of 0.4 ml/min. The mobile phases were 10 mm ammonium acetate (ph 4.3) and acetonitrile. The proportion of acetonitrile was increased linearly from 0 to 60% during 40 min. Acetonitrile reached 80% at 45 min and was held constant until 50 min. Mephenytoin was chromatographed at 25 C (C18 Genesis, 4 m, mm; Jones Chromatography Inc., Lakewood, CO). The mobile phases were 20 mm ammonium acetate (ph 7.4) and acetonitrile with a total flow rate of 0.6 ml/min. The proportion of acetonitrile was increased linearly from 0 to 100% during 30 min. Diclofenac was chromatographed at 40 C (LC 18-DB, 5- m particle size, mm and mm) at a total flow of 1 ml/min. The mobile phase consisted of 100 mm sodium phosphate (80%) and acetonitrile (20%) containing triethylamine (0.02%). Fluvastatin, glyburide, and their metabolites were detected by radioactivity monitoring using -Ram (IN/US Systems Inc., Tampa, FL) and glibornuride and alternatively glyburide by UV detection at 230 and 238 nm, respectively. Diclofenac and its 4 -hydroxy-metabolite were monitored by electrochemical detection using a Coulochem II (ESA, Inc., Bedford, MA). All other compounds were analyzed essentially as described by Fischer et al. (1998). All compounds and metabolites were identified by their HPLC retention times and compared to chromatograms of reference compounds. Fluvastatin metabolites were additionally identified by liquid chromatography/mass spectrometry (LC/MS) analysis. Mass Spectrometric Analysis. Liquid chromatography flow was split equally between the TSQ-7000 mass spectrometer (Finnigan MAT, San Jose, CA) and an INUS -Ram radioactivity monitor. Single and tandem quadrupole experiments were performed in the negative ion mode with an electrospray interface. Capillary temperature was 225 C and gas pressures were set at four bars for nitrogen sheath gas and one bar for nitrogen auxiliary gas. For most experiments, the electron multiplier setting was 1600 V. For tandem MS experiments, the collision cell voltage was 25 ev and the argon cell pressure was bar. Data Analysis. Metabolic rates were calculated from mean substrate concentrations over the incubation period. values were determined graphically by plotting the percent of the control activity against the inhibitor concentration. Michaelis-Menten parameters K m and V max were determined by analysis of linearized plots as well as nonlinear curve fitting using Hyper.exe
3 412 FISCHER ET AL. FIG. 1.Fluvastatin metabolite profiles in human liver microsomes and individual CYP2C9 and CYP3A4. Typical HPLC separation with radioactivity monitoring of fluvastatin and its metabolites formed in incubations of [ 14 C]fluvastatin (0.6 M) during 30 min with human liver microsomal protein (200 g/ml) (A) or baculovirus insect cell-expressed CYP2C9 R144 (B) and CYP3A4 (C) (1 mg cellular protein/ml). (Easterby, Department of Biochemistry, University of Liverpool, Liverpool, UK) and Fig.P (BIOSOFT, Cambridge, UK) with the following equation: V V max [S]/K m [S] Maximal velocities of fluvastatin metabolite formation by recombinant enzymes were extrapolated to human liver microsomes using the ratio of reference activities in the respective systems. Testosterone metabolism (CYP3A), diclofenac 4-hydroxylation (CYP2C9), and 6 -hydroxy-paclitaxel formation (CYP2C8) were used as reference activities (Crespi and Penman, 1997). Using a model for mixed-type inhibition, the K i values were calculated with the following equation (Segel, 1993): K i [I]/[(K m,i /K m,u )(V max,u /V max,i ) 1] where K m,i and K m,u are the Michaelis-Menten constants and V max,i and V max,u are the maximal velocities in the presence and absence of inhibitor, respectively. The in vitro intrinsic metabolic clearance was calculated by dividing the maximal rate of metabolism by the Michaelis-Menten constant, according to the equation: CL int V max /K m Results Biotransformation Pathways. Fluvastatin was metabolized in five different human liver microsomal preparations to three primary metabolites (Figs. 1A and 2). The metabolites exhibiting retention times of 42 and 45 min were identified as 6-hydroxy- and 5-hydroxyfluvastatin, respectively, and the metabolite eluting at 52 min was FIG. 2.Metabolite pathways of fluvastatin in human liver microsomes and human P-450s. identified as -fluvastatin. The assignment of the metabolite structures was based on LC/MS analysis and on retention times compared with synthetic reference compounds. The LC/MS analysis indicated changes of the nominal mass compared to fluvastatin of M 16 for 5-hydroxy- and 6-hydroxy-fluvastatin and of M 42 for fluvastatin. Quantitatively, at 0.2 to 0.6 M fluvastatin concentrations in human liver microsomes, 5-hydroxy-fluvastatin was the most abundant metabolite, followed by 6-hydroxy-fluvastatin and -fluvastatin, which were of similar importance. Among the five livers studied, 5-hydroxy-fluvastatin formation varied 2- to 29-fold compared to 6-hydroxy-fluvastatin (data not shown), whereas there was less variability between 6-hydroxy-fluvastatin and -fluvastatin formation ( fold). Individual human P-450 isoenzymes expressed in human lymphoblast cells or in insect cells also metabolized fluvastatin, but only CYP2C9 formed all three metabolites produced by human liver microsomes (Fig. 1B). Recombinant human CYP3A4 (Fig. 1C), CYP2C8, CYP2D6, and CYP1A1 (data not shown) formed only 5-hydroxy-fluvastatin. Quantitatively, for CYP2C9, 6-hydroxyfluvastatin is the most abundant metabolite, followed by 5-hydroxyand -fluvastatin. There was no difference in fluvastatin metabolite formation between the CYP2C9 R144 allele and the CYP2C9 C144 allele. In contrast, CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2E1, and CYP3A5 did not produce detectable amounts of metabolites (data not shown). Intrinsic Metabolic Clearance. The rate of fluvastatin metabolism was determined for three human liver microsomal preparations over a concentration range of 0.04 to 20 M (Table 1) and for recombinant CYP2C8, CYP2C9, and CYP3A4 preparations (Table 2). In human liver microsomal preparations, metabolism appeared biphasic. For the lower substrate concentration ( M), the K m was similar for
4 FLUVASTATIN METABOLISM AND DRUG INTERACTIONS 413 TABLE 1 Enzyme kinetic parameters for fluvastatin metabolism The apparent K m and V max were determined for fluvastatin metabolite formation by human liver microsomal protein ( M) using nonlinear regression analysis. Biphasic analysis was performed between 0.04 and 0.6 M or 0.6 and 20 M, respectively. Human Liver Metabolites K m1 K m2 V max1 V max2 Cl int1 Cl int2 M M nmol/h/mg nmol/h/mg ml/h/mg ml/h/mg GGM-002 All OH M8 All OH HL45 All OH TABLE 2 Individual enzyme kinetic parameters for fluvastatin metabolism Michaelis-Menten parameters were determined from recombinant baculovirus/insect cell microsomes expressing active, human CYP2C8, CYP2C9 R144, CYP2C9 C144, or CYP3A4. Maximal velocities were extrapolated to human liver microsomes using the ratio of reference activities in a panel of human liver microsomes compared recombinant with enzymes: CYP3A, testosterone; CYP2C9, diclofenac; CYP2C8 6 -hydroxy-paclitaxel (Crespi and Penman, 1997). Recombinant Enzymes Enzyme/Metabolite K m nmol/h/nmol V max CYP (nmol/h/mg protein) all three livers ( M), whereas the V max values ranged from 0.3 to 2.6 nmol/h/mg microsomal protein. At the higher concentrations ( M), K m values were 24 to 35 M with V max values ranging from 7.9 to 50 nmol/h/mg microsomal protein. This second phase contributed about 20 to 30% to the total intrinsic metabolic clearance of fluvastatin. For the formation of 6-hydroxy-fluvastatin and -fluvastatin ( M), K m values were 0.1 to 0.3 M, which is similar to the high K m component for total metabolism. V max values for the formation of 6-hydroxy-fluvastatin and -fluvastatin were between 0.1 and 0.6 nmol/h/mg human liver microsomal protein. Human enzymes CYP2C9 R144 and CYP2C9 C144 each exhibited a K m of 1 M and the V max values were also similar for both CYP2C9 alleles. The K m values observed for CYP2C8 and CYP3A4 were higher (i.e., 2.8 and 7.1 M, respectively). The maximal velocities were extrapolated to human liver microsomes as described in Materials and Methods. The sum of the metabolic clearance estimates for recombinant CYP3A and CYP2C9 extrapolated for human liver microsomes was about 3-fold below the total intrinsic metabolic clearance estimates obtained from human liver microsomal incubations. Based on these calculations, the contribution of CYP2C9 and CYP3A to human liver fluvastatin metabolic clearance was similar. Inhibition of Fluvastatin Metabolism. Only compounds known to inhibit either CYP2C9 or CYP3A decreased fluvastatin metabolism (Table 3). Substrates and inhibitors of CYP2C9 such as diclofenac, warfarin, and sulfaphenazole inhibited all pathways of fluvastatin metabolism, but the largest effects were on the CYP2C9-catalyzed 6-hydroxy- and N- Human Liver Microsomes (Extrapolated Contribution of Isoenzyme) V max nmol/h/nmol CYP (nmol/h/mg protein) Cl mt ml/h/nmol CYP (ml/h/mg protein) M CYP 3A4/5-OH a (29) 14 (5.7) 1.9 (0.8) CYP 2C9 R144 /6-OH (2.4) 1.1 (0.5) 1.2 (0.5) CYP 2C9 R144 /5-OH (1.2) 0.5 (0.2) 0.5 (0.2) CYP 2C9 R144 / (1.2) 0.4 (0.2) 0.2 (0.1) CYP 2C9 C144 /6-OH (1.7) 1.1 (0.5) 0.9 (0.4) CYP 2C9 C144 /5-OH (0.7) 0.5 (0.2) 0.5 (0.2) CYP 2C9 C144 / (0.8) 0.5 (0.2) 0.4 (0.2) CYP 2C8/5-OH (2.9) 0.2 (0.3) 0.1 (0.1) a mean of two experiments deisopropyl-fluvastatin formation. Typical CYP3A-specific inhibitors such as ketoconazole and troleandomycin were only inhibitory for 5-hydroxy-fluvastatin formation, which is in part formed by CYP3A. Compounds such as phenacetin and furafylline did not affect metabolism of fluvastatin. Both are known to inhibit CYP1A2. Similarly, substrates of CYP2D6 (quinidine, dextromethorphan, and sparteine) or CYP2E1 (chlorzoxazone) had no relevant effect on fluvastatin metabolism. Among the antihypertensive agents that might potentially be coadministered with fluvastatin, both nifedipine and isradipine were almost equally inhibitory of all three metabolites ( 2 7 M). Mibefradil only partially inhibited the formation of 5-hydroxyfluvastatin, a metabolite that can be formed by several enzymes. Valsartan had no effect on fluvastatin metabolism. Among the antifungal agents, ketoconazole was the only compound that inhibited one of the metabolites, i.e., 5-hydroxy-fluvastatin formation. Itraconazole and terbinafine had little or no effect on any metabolite. The antihypercholesterolemic agents, lovastatin and clofibrate, inhibited both CYP2C9 and CYP3A ( 5 10 M), whereas pravastatin had no effect. The immunosuppressant cyclosporine A had only small inhibitory effect at high concentrations, which is consistent with clinical observations. Finally, the antidiabetic chlorpropamide had no effect on fluvastatin metabolism, whereas glyburide, and, to a lesser extent, tolbutamide were inhibitory of all fluvastatin metabolic pathways. Effect of Fluvastatin on the Metabolism of other Drugs. Fluvastatin inhibited only the metabolism of compounds that are metabolized by CYP2C9 (Table 4). Fluvastatin was found to inhibit the metabolism of the CYP2C9 substrates diclofenac and tolbutamide.
5 414 FISCHER ET AL. TABLE 3 Inhibition of fluvastatin metabolism [ 14 C]Fluvastatin (0.6 M) metabolism by human liver microsomes (M8) was determined in the presence of various concentrations of characteristic inhibitors/substrates and potentially coadministered compounds. Inhibitory concentrations ( ) were determined as described in Materials and Methods. Inhibitor/Substrate Inhibition of 6-OH Inhibition of 5-OH Inhibitor/Substrate Inhibition of 6-OH Inhibition of 5-OH M M M M Analgesic/antipyretic: Steroids: Diclofenac 3 20 Ethinyl estradiol 3 5 Phenacetin Antitussive: Sulfinpyrazone Dextromethorphan Antihypertensive: Antiarrhythmic: Nifedipine Quinidine Mibefradil a 60 1 Sparteine Isradipine b 4 4 Antihypercholesterolemic: Valsartan Lovastatin 7 5 Immunosuppressant: Pravastatin b Cyclosporine A Clofibrate 10 9 Antibiotic: Anticoagulant: Erythromycin Warfarin 8 9 Antidiabetic: Skeletal muscle relaxant: Chlorpropamide Chlorzoxazone Glyburide 5 9 Anti Asthmatic: Tolbutamide Furafylline Antifungal: Antibacterial: Ketoconazole 90 8 Sulfaphenazole Itraconazole a Troleandomycin Terbinafine b Antineoplastic: Paclitaxel 8 10 Additional human livers used were: a M8 HL44 HL46, b M8 HL44 TABLE 4 Effect of fluvastatin on the metabolism of characteristic cytochrome P-450 substrates and potentially coadministered compounds ( ) in human liver microsomes Substrate K i Pathway Enzyme M M Phenacetin 100 O-Deethylation CYP1A2 Paclitaxel Hydroxylation CYP2C8 Tolbutamide Hydroxylation CYP2C9 Diclofenac Hydroxylation CYP2C9 (S)-Mephenytoin Hydroxylation CYP2C19 Cyclosporine A 100 Hydroxylation CYP3A N-Demethylation Glibornuride Glyburide Cyclohexyl hydroxylation FIG. 3.Lineweaver-Burk plots of tolbutamide 4-hydroxylation. Human liver microsomal incubations of 0.7 to 100 M tolbutamide were performed in the presence of 0, f; 0.1, F; 1, ; and 5 M fluvastatin,. For tolbutamide 4-hydroxylation, which displayed monophasic Michaelis-Menten kinetics (Fig. 3), the maximal velocity (V max ) and Michaelis-Menten constant (K m ) were 17 nmol/h/mg and 160 M, respectively. In the presence of fluvastatin (5 M), there was an increase in K m to 1.3 mm and only a relative small decrease in V max as expected for a competitive inhibition. The mean inhibition constant (K i ) for three inhibitor concentrations was 0.3 M. Diclofenac also exhibited monophasic Michaelis-Menten kinetics with a K m of 9.4 M and a V max of 170 nmol/h/mg. K m increased to 31 M and V max decreased to 95 nmol/h/mg in the presence of 1 M fluvastatin. This is indicative of a mixed mode of inhibition with a mean K i of 0.5 M for three fluvastatin concentrations. Glyburide metabolism in human liver microsomes exhibited monophasic Michaelis-Menten kinetics, with a V max of 33 nmol/h/mg protein and a K m of 8.4 M. Several metabolites were detected, which correspond to hydroxylations at the phenylethyl moiety and at the cyclohexyl ring (Fischer et al., 1998). Fluvastatin selectively inhibited cyclohexyl hydroxylation of glyburide but had little effect on phenylethyl hydroxylation of glyburide. The inhibition of cyclohexyl hydroxylation of glyburide by fluvastatin was predominantly competitive as indicated by a 3-fold increase in K m from9to27 M with only a 30% decrease in V max from 320 to 230 nmol/h/mg for the highest 20 M fluvastatin concentration. The K i value was thus determined to be M. Sulfaphenazole, a specific inhibitor of CYP2C9, also specifically inhibited glyburide cyclohexyl hydroxylation with an of 20 M (data not shown). Glibornuride was metabolized to four unidentified metabolites in incubations with human liver microsomes. Metabolism followed monophasic Michaelis-Menten kinetics
6 FLUVASTATIN METABOLISM AND DRUG INTERACTIONS 415 with a maximal velocity V max of 81 nmol/h/mg protein and a K m of 120 M. In contrast with glyburide, the inhibition by fluvastatin of glibornuride metabolism was noncompetitive. The mean K i calculated was M. Sulfaphenazole also inhibited glibornuride metabolism with an of 10 M (data not shown). Discussion The combined data indicate that fluvastatin is metabolized by multiple enzymes. Specifically, the metabolites that are primarily responsible for the elimination of fluvastatin (Dain et al., 1993) are formed by several enzymes: 5-hydroxy-fluvastatin by CYP2C9 and 6-hydroxy- and deisopropyl-fluvastatin mainly by CYP2C9, CYP3A4, and CYP2C8. The most relevant enzyme for in vivo metabolic clearance of fluvastatin is predicted to be CYP2C9, because it is the only one forming all three metabolites found in vivo. All other enzymes capable of metabolizing fluvastatin produced only the 5-hydroxy-fluvastatin metabolite. The relative contribution of 6-hydroxyand -fluvastatin could therefore serve as an indicator for the contribution of CYP2C9 to fluvastatin elimination. In four healthy human volunteers, the contribution of CYP2C9 appeared to be 65% of fluvastatin elimination based on fecal metabolite profiles (Dain et al., 1993). CYP2C9 also appears to be responsible for the high K m component, which contributes 73 to 83% to total fluvastatin metabolism in human liver microsomes. The apparent K m for this component is similar to the K i for the inhibition of CYP2C9 substrates, such as tolbutamide and diclofenac, by fluvastatin. Also specific CYP2C9 inhibitors, such as sulfaphenazole (Baldwin et al., 1995), strongly inhibit 6-hydroxy- and -fluvastatin formation but only inhibited to a limited extent 5-hydroxy-fluvastatin formation. In contrast, ketoconazole, a specific inhibitor of CYP3A (Baldwin et al., 1995), inhibited only 5-hydroxy-fluvastatin formation. Furthermore, the ketoconazole concentration required for a 50% inhibition of 5-hydroxy-fluvastatin formation was greater than would be expected for a reaction that is catalyzed only by CYP3A. This suggests the involvement of enzymes other than CYP3A in this pathway. For the individual enzymes, the K m of recombinant CYP2C9 fluvastatin metabolism corresponded most closely to the higher K m component in human liver microsomes, whereas the K m of recombinant CYP3A for fluvastatin exhibits a lower K m, possibly reflecting the lower K m component observed in human liver. Both CYP2C9 and CYP3A would thus be predicted to be the major enzymes involved in fluvastatin metabolism. Overall, fluvastatin appears to be metabolized in human liver by several enzymes, with CYP2C9 being the most important, followed by CYP3A4 and CYP2C8. There was no difference in fluvastatin intrinsic metabolic clearance for CYP2C9 R144 and the variant allele CYP2C9 C144, which has been associated with a smaller warfarin maintenance dose in heterozygotes (Furuya et al., 1995). Based on the present data, no difference in fluvastatin clearance is expected in patients which express CYP2C9 C144. The involvement of several enzymes in the metabolism of fluvastatin should minimize the effect, in case a coadministered compound inhibits one enzyme. Clinical observations confirm these findings. For example, neither CYP2C9 inhibitors/substrates such as the antidiabetics tolbutamide and glyburide, the anticoagulant warfarin, or the proton pump inhibitor omeprazole (Appel and Dingemanse, 1996) nor CYP3A inhibitors/substrates such as the immunosuppressive cyclosporine A or the antifungal itraconazole had significant clinical effects on fluvastatin. Furthermore, even a compound such as isradipine, which inhibits both CYP2C9- and CYP3A-mediated pathways of fluvastatin metabolism in vitro, is not expected to have a clinically significant effect, because isradipine plasma concentrations are 80-fold lower than the in vitro values. Fluvastatin appears also to be safe with respect to its potential effect on other compounds. Fluvastatin was previously reported to inhibit CYP2C9 but not CYP3A and CYP2D6 in vitro (Transon et al., 1996). The present data confirm these findings and demonstrate that fluvastatin does not inhibit CYP1A2, CYP2C8, CYP2C19, or CYP3A. Only small effects on coadministered CYP2C9 substrates were also observed in vivo, in spite of the relatively potent inhibition of CYP2C9 in vitro. Compounds such as diclofenac, warfarin, tolbutamide, or glyburide were only minimally affected, with only C max being increased (Transon et al., 1995; Appel and Dingemanse, 1996). This can be explained by the short terminal half-life of fluvastatin of 0.5 to 1 h, which would suggest that fluvastatin can inhibit CYP2C9 mainly during first-pass. In summary, fluvastatin has a low potential for metabolic drug-drug interactions as compared to other HMG-CoA reductase inhibitors. Multiple enzymes are involved in the metabolism of fluvastatin, with CYP2C9 as the major one. Conversely, although fluvastatin is a potent inhibitor of CYP2C9, this effect is limited because of fluvastatin s rapid systemic clearance. As a consequence, fluvastatin inhibits coadministered compounds metabolism only during first-pass. Acknowledgments. We thank Dr. T. Ray and Dr. H. Andres for the synthesis of the radiolabeled fluvastatin, and Dr. C. Crespi for the helpful discussions. References Appel S and Dingemanse J (1996) Pharmacokinetic and pharmacodynamic interactions of fluvastatin and their therapeutic implications. Rev Contemp Pharmacother 7: Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25: Ball SE, Maurer G, Zollinger M, Ladona M and Vickers AEM (1992) Characterization of the cytochrome P-450 gene family responsible for N-dealkylation of the ergot alkaloid CQA in humans. Drug Metab Dispos 20: Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J and Radtke M (1997) Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25: Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: Crespi CL and Penman BW (1997) Use of cdna-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 43: Dain JG, Fu E, Gorski J, Nicoletti J and Scallen TJ (1993) Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 21: Davidson MH (1994) Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am J Med 96:S41 S44. Dimitroulakos J and Yeger H (1996) HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein expressing cells. Nature Med 2: Fischer V, Rodríguez-Gascón A, Heitz F, Tynes R, Hauck C, Cohen D and Vickers AEM (1998) The multidrug resistance modulator PSC 833 is metabolized by CYP3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26: Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ and Idle JR (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5: Goldberg R and Roth D (1996) Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation (Baltimore) 62: Ikeda T, Ishigami M, Komai T and Yamazoe Y (1997) Inhibition of hepatic cytochrome P450 isoform, CYP3A, by 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Atherosclerosis 134:135. Kantola T, Kivistö KT and Neuvonen PJ (1997) Differential effects of itraconazole on fluvastatin and lovastatin pharmacokinetics. Eur J Clin Pharmacol 52:A134. Lees RS and Lees AM (1995) Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 333:664. Levy RI, Troendle AJ and Fattu JM (1993) A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 87(Suppl 4):III45 III53. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O Grady P, Krekler M, Mangold B and Christians U (1997) Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62: Omura T and Sato R (1964) The carbon-monoxide binding pigment of liver microsomes. J Biol Chem 239:
7 416 FISCHER ET AL. Peters TK (1996) Safety profile of fluvastatin. Br J Clin Pract S77a: Peters TK, Jewitt-Harris J, Mehra M and Muratti EN (1993) Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents: An analysis of a clinical trial database. Am J Hypertens 6:S346 S352. Physicians Desk Reference (1998) 52nd ed, p Medical Economics Company, Inc., Montvale, NJ. Plosker GL and Wagstaff AJ (1996) Fluvastatin: A review of its pharmacology and use in the management of hypercholesteraemia. Drugs 51: Prueksaritanont T, Gorham, LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH and Vyas KP (1997) In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25: Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, Gavazzi A and Vigano M (1993) Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 25: Segel IH (1993) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, pp , John Wiley & Sons, New York. Tobert JA (1988) Efficacy and long-term adverse effects pattern of lovastatin. Am J Cardiol 62:J28 J34. Transon C, Leemann T and Dayer P (1996) In vitro comparative inhibition of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 50: Transon C, Leemann T, Vogt N and Dayer P (1995) In vivo inhibition profile of cytochrome P450TB (CYP2C9) by ( )fluvastatin. Clin Pharmacol Ther 58: Tse FLS, Jaffe JM and Troendle A (1992) Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32: Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP and Vyas KP (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290:
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin K. T. Kivistö, T. Kantola & P. J. Neuvonen Department of Clinical Pharmacology, University of Helsinki and Helsinki
More informationPilot experiments to investigate the glucuronidation of axitinib with human liver microsomes.
Zientek MA, Goosen TC, Tseng E, Lin J, Bauman JN, Walker GS, Kang P, Jiang Y, Freiwald S, Neul D and Smith BJ. In Vitro Kinetic Characterization of Axitinib Metabolism. Drug Metab Dispos. Supplemental
More informationDRUG INTERACTION BETWEEN SIMVASTATIN AND ITRACONAZOLE IN MALE AND FEMALE RATS
0090-9556/01/2907-1068 1072$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 7 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 331/915884 DMD 29:1068 1072, 2001 Printed
More informationInvolvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338
Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338 S. Furuta 1, E. Kamada 1, T. Sugimoto 1, Y. Kawabata 1, X. C. Wu 2, J. Skibbe 3, E. Usuki 3, A. Parkinson 3 and
More informationIN VITRO IDENTIFICATION OF THE HUMAN CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF R( )- AND S( )-CARVEDILOL
0090-9556/97/2508-0970 977$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 25, No. 8 Copyright 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. IN VITRO IDENTIFICATION
More informationArena Pharmaceuticals, Inc., Department of Drug Metabolism and Pharmacokinetics, San Diego, California
1521-009X/12/4004-761 771$25.00 DRUG METABOLISM AND DISPOSITION Vol. 40, No. 4 Copyright 2012 by The American Society for Pharmacology and Experimental Therapeutics 43414/3759637 DMD 40:761 771, 2012 Identification
More informationMULTIPLE CYTOCHROME P-450s INVOLVED IN THE METABOLISM OF TERBINAFINE SUGGEST A LIMITED POTENTIAL FOR DRUG-DRUG INTERACTIONS
0090-9556/99/2709-1029 1038$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 9 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. MULTIPLE CYTOCHROME
More information(Received April 8, 1998; accepted July 30, 1998) This paper is available online at ABSTRACT:
0090-9556/99/2702-0173 179$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 2 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. COMPARISON OF CYTOCHROME
More informationMetabolism and metabolic inhibition of cilnidipine in human liver microsomes 1
263 2003, Acta Pharmacologica Sinica Chinese Pharmacological Society Shanghai Institute of Materia Medica Chinese Academy of Sciences http://www.chinaphar.com Metabolism and metabolic inhibition of cilnidipine
More informationMetabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes
Virginia Commonwealth University VCU Scholars Compass Medicinal Chemistry Publications Dept. of Medicinal Chemistry 216 Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes Zhongnv
More informationCulture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug Interaction. Chuang Lu
Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug nteraction Chuang Lu Millennium, The Takeda Oncology Company Cambridge, MA, USA DD 205, Seattle, 6/29/205
More informationReceived May 30, 2007; accepted August 15, 2007
0090-9556/07/3511-1990 1995$20.00 DRUG METABOLISM AND DISPOSITION Vol. 35, No. 11 Copyright 2007 by The American Society for Pharmacology and Experimental Therapeutics 16816/3267964 DMD 35:1990 1995, 2007
More informationQuantification of lovastatin in human plasma by LC/ESI/MS/MS using the Agilent 6410 Triple Quadrupole LC/MS system
Quantification of lovastatin in human plasma by LC/ESI/MS/MS using the Agilent 641 Triple Quadrupole LC/MS system Application Note Clinical Research Author Siji Joseph Agilent Technologies Bangalore, India
More informationA mong the 20 leading prescription
Safety and Statins: Pharmacologic and Clinical Perspectives Michael B. Bottorff, PharmD A mong the 20 leading prescription drugs in the United States, 3 agents atorvastatin (Lipitor), simvastatin (Zocor),
More informationGLUCURONIDATION OF STATINS IN ANIMALS AND HUMANS: A NOVEL MECHANISM OF STATIN LACTONIZATION
0090-9556/02/3005-505 512$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 5 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 623/975196 DMD 30:505 512, 2002 Printed
More informationIn vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases
In vitro metabolism of montelukast by Cytochrome P450s (CYPs) and UDPglucuronosyltransferases (UGTs) Josiane de Oliveira Cardoso, Regina Vincenzi Oliveira, Jessica Bo Li Lu Zeruesenay Desta Department
More informationXTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose
XTreme 200 Human Liver Microsomes Lot No. 1710084 Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose H2610 0.5 ml at 20 mg/ml H2620 1.0 ml at 20 mg/ml H2630
More informationInternational Journal of Pharma and Bio Sciences DETERMINATION OF SIMVASTATIN IN HUMAN PLASMA USING LIQUID CHRMATOGRAPHY-MASS SPECTROMETRY ABSTRACT
Research Article Nanotechnology International Journal of Pharma and Bio Sciences ISSN 0975-6299 DETERMINATION OF SIMVASTATIN IN HUMAN PLASMA USING LIQUID CHRMATOGRAPHY-MASS SPECTROMETRY KHALED. M. ALAKHALI
More informationLarge interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity
et al. DOI:1.146/j.1365-2125.3.197.x British Journal of Clinical Pharmacology Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity
More informationLack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Publishing 200254Original ArticleCo-administration of rosuvastatin and ketoconazolek. J. Cooper Lack of effect
More informationSorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and
Supplemental Methods Chemicals and Reagents Sorafenib (free base, >99%) was obtained from Chemie Tek (Indianapolis, IN), and isotopically-labeled 13 C- 2 H 3 -sorafenib (labeled atoms on N-methyl position)
More informationHigh-Throughput CYP Inhibition Screening with Drug Probe Substrates: The RapidFire Advantage
High-Throughput CYP Inhibition Screening with Drug Probe Substrates: The RapidFire Advantage David M. Stresser, Ph.D. Program Manager BD Gentest SM Contract Research Services November 11, 2009 Presentation
More informationWithdrawal of Cerivastatin Revealed a Flaw of Post-marketing Surveillance System in the United States
Bull. Natl. Inst. Health Sci., 123 Notes # Withdrawal of Cerivastatin Revealed a Flaw of Post-marketing Surveillance System in the United States Journal of American Medical Association (JAMA) Statin HMG
More informationStatin inhibition of HMG-CoA reductase: a 3-dimensional view
Atherosclerosis Supplements 4 (2003) 3/8 www.elsevier.com/locate/atherosclerosis Statin inhibition of HMG-CoA reductase: a 3-dimensional view Eva Istvan * Department of Molecular Microbiology, Howard Hughes
More informationIdentification & Confirmation of Structurally Related Degradation Products of Simvastatin
Identification & Confirmation of Structurally Related Degradation Products of Simvastatin Power of QTRAP Systems for Identification and Confirmation of Degradation Products Dilip Reddy 1, Chandra Sekar
More informationAND LIVER MICROSOMAL P-450 PROFILES
0090-9556/99/2706-0655 666$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 6 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. DEVELOPMENT OF
More informationCYTOCHROME P450 3A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES
0090-9556/05/3304-500 507$20.00 DRUG METABOLISM AND DISPOSITION Vol. 33, No. 4 Copyright 2005 by The American Society for Pharmacology and Experimental Therapeutics 836/1197409 DMD 33:500 507, 2005 Printed
More informationJose Castro-Perez, Henry Shion, Kate Yu, John Shockcor, Emma Marsden-Edwards, Jeff Goshawk Waters Corporation, Milford, MA, U.S. and Manchester, UK
HIGH-THRUGHPUT REACTIVE METABLITE SCREEIG FR DICLFEAC BY UPLC AD XEV TQ MS WITH SCAWAVE Jose Castro-Perez, Henry Shion, Kate Yu, John Shockcor, Emma Marsden-Edwards, Jeff Goshawk Waters Corporation, Milford,
More informationDetermination of Clarithromycin in Human Plasma by LC-EI Tandem Mass Spectrometry: Application to Bioequivalence Study
Determination of Clarithromycin in Human Plasma by LC-EI Tandem Mass Spectrometry: Application to Bioequivalence Study Syed N Alvi, Ph.D Clinical Studies & Empirical Ethics Department King Faisal Specialist
More informationCYTOCHROME P450: Structure-Function
MEDCH 527 AE Jan. 4-6, 2017 CYTCHME P450: Structure-Function 1. General P450 Characteristics and Taxonomy 2. Human P450s Substrate and Inhibitor Selectivities 3. Structure-Function Aspects of Ligand Binding,
More informationDesigner Fentanyls Drugs that kill and how to detect them. Cyclopropylfentanyl
Designer Fentanyls Drugs that kill and how to detect them Cyclopropylfentanyl Science for a safer world The in vitro metabolism of cyclopropylfentanyl Simon Hudson & Charlotte Cutler, Sport and Specialised
More informationUltra Performance Liquid Chromatography Coupled to Orthogonal Quadrupole TOF MS(MS) for Metabolite Identification
22 SEPARATION SCIENCE REDEFINED MAY 2005 Ultra Performance Liquid Chromatography Coupled to Orthogonal Quadrupole TOF MS(MS) for Metabolite Identification In the drug discovery process the detection and
More informationDifferential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
Differential selectivity of cytochrome P4 inhibitors against probe substrates in human and rat liver microsomes Victoria A. Eagling, John F. Tjia & David J. Back Department of Pharmacology & Therapeutics,
More informationCYTOCHROME P450 2C8 AND FLAVIN-CONTAINING MONOOXYGENASES ARE INVOLVED IN THE METABOLISM OF TAZAROTENIC ACID IN HUMANS
0090-9556/03/3104-476 481$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 4 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 895/1052414 DMD 31:476 481, 2003 Printed
More informationCYTOCHROME P-450 3A4 AND 2C8 ARE INVOLVED IN ZOPICLONE METABOLISM
0090-9556/99/2709-1068 1073$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 9 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. CYTOCHROME P-450
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Prevymis TM GENERIC NAME Letermovir MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL November 9, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of new
More informationChuang Lu, Suresh K. Balani, Mark G. Qian, Shimoga R. Prakash, Patricia S. Ducray, and Lisa L. von Moltke
0022-3565/10/3322-562 568$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 332, No. 2 Copyright 2010 by The American Society for Pharmacology and Experimental Therapeutics 161893/3550697
More informationIN VITRO BIOTRANSFORMATION OF SILDENAFIL (VIAGRA): IDENTIFICATION OF HUMAN CYTOCHROMES AND POTENTIAL DRUG INTERACTIONS
0090-9556/00/2804-0392 397$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 4 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. IN VITRO BIOTRANSFORMATION
More informationKARTHIK VENKATAKRISHNAN, LISA L. VON MOLTKE, and DAVID J. GREENBLATT
0022-3565/01/2971-326 337$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 297, No. 1 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 3324/893791
More informationINVOLVEMENT OF CYP2E1 AS A LOW-AFFINITY ENZYME IN PHENACETIN O-DEETHYLATION IN HUMAN LIVER MICROSOMES
0090-9556/99/2708-0860 865$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 8 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. INVOLVEMENT OF
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationO O H. Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL. LC /MS conditions
Simplifying Qual/Quan Analysis in Discovery DMPK using UPLC and Xevo TQ MS Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION The determination of the drug metabolism
More informationAFPC Conference InterMed-Rx : Harmony and optimal therapy in the use of medication. June
AFPC Conference 2009 InterMed-Rx : Harmony and optimal therapy in the use of medication June 5 2009 Jacques Turgeon, B.Pharm., Ph.D. Full professor, Faculty of pharmacy Research Director, CHUM Université
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationFarmacologia di genere. Prof. Alberto Corsini Università degli Studi di Milano
Farmacologia di genere Prof. Alberto Corsini Università degli Studi di Milano Women have been less enrolled in clinical trials A gender-specific analysis usually is not included in the evaluation of results
More informationMetabolism of the active metabolite of quetiapine, N-desalkylquetiapine, in
DMD Fast This article Forward. has not been Published copyedited on and June formatted. 11, The 2012 final version as doi:10.1124/dmd.112.045237 may differ from this version. Metabolism of the active metabolite
More informationCurrent Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 Definition Phenotyping is quantifying the in vivo activity
More informationDevelopment and Validation of HPLC-UV Method for Simultaneous Determination of Nevirapine, 2-OH Nevirapine and 3-OH Nevirapine in Human Plasma.
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.6, No.1, pp 49-57, Jan-March 2014 Development and Validation of HPLC-UV Method for Simultaneous Determination of Nevirapine,
More informationINTERACTION OF DELAVIRDINE WITH HUMAN LIVER MICROSOMAL CYTOCHROME P450: INHIBITION OF CYP2C9, CYP2C19, AND CYP2D6
0090-9556/01/2901-41 47$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 1 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 147/871984 DMD 29:41 47, 2001 Printed in
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationIdentification of ginkgolide B metabolites in urine and rat liver cytochrome P450 enzymes responsible for their formation in vitro 1
Acta Pharmacol Sin 2008 Mar; 29 (3): 376 384 Full-length article Identification of ginkgolide B metabolites in urine and rat liver cytochrome P450 enzymes responsible for their formation in vitro 1 Dian-lei
More informationPathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine S
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2008/05/07/dmd.107.019562.dc1 0090-9556/08/3608-1637 1649$20.00 DRUG METABOLISM AND DISPOSITION Vol. 36,
More informationUnique Retention and Selectivity of Pentafluorophenylpropyl Phases for High-Throughput LC/MS Analysis
Unique Retention and Selectivity of Pentafluorophenylpropyl Phases for High-Throughput LC/MS Analysis David S. Bell Supelco, Bellefonte, PA ASMS 22 T42119 (xxx) Overview 2 The LC/MS retention and sensitivity
More informationELIZABETH A. DIERKS, KAREN R. STAMS, HENG-KEANG LIM, GEORGIA CORNELIUS, HONGLU ZHANG, AND SIMON E. BALL 2
0090-9556/01/2901-23 29$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 1 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 207/875364 DMD 29:23 29, 2001 Printed in
More informationAn Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes
9-9556/11/398-137 1387$25. DRUG METABOLISM AND DISPOSITION Vol. 39, No. 8 Copyright 211 by The American Society for Pharmacology and Experimental Therapeutics 38596/3724 DMD 39:137 1387, 211 Printed in
More informationANTHONY J. LEE, JOSEPH W. KOSH, ALLAN H. CONNEY, 1 and BAO TING ZHU. ABSTRACT We characterized the NADPH-dependent metabolism of 17 estradiol
0022-3565/01/2982-420 432$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 298, No. 2 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 3751/916932
More informationStereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 49-OH-bupropion in vitro
1521-009X/44/10/1709 1719$25.00 http://dx.doi.org/10.1124/dmd.116.072363 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:1709 1719, October 2016 Copyright ª 2016 by The Author(s) This is an open access
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationIntroduction. C. Prakash, 1 A. Kamel, 1 D. Cui, 1 R. D. Whalen, 1 J. J. Miceli 2 & D. Tweedie 1 35S
Identi cation of the major human liver cytochrome P45 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions C. Prakash, 1 A. Kamel,
More informationDAPSONE ACTIVATION OF CYP2C9-MEDIATED METABOLISM: EVIDENCE FOR ACTIVATION OF MULTIPLE SUBSTRATES AND A TWO-SITE MODEL
0090-9556/01/2907-1029 1034$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 7 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 352/914007 DMD 29:1029 1034, 2001 Printed
More informationEVALUATION OF CYTOCHROME P450 PROBE SUBSTRATES COMMONLY USED BY THE PHARMACEUTICAL INDUSTRY TO STUDY IN VITRO DRUG INTERACTIONS
0090-9556/02/3012-1311 1319 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 12 U.S. Government work not protected by U.S. copyright 548/1028208 DMD 30:1311 1319, 2002 Printed in U.S.A. EVALUATION OF CYTOCHROME
More informationMS/MS as an LC Detector for the Screening of Drugs and Their Metabolites in Race Horse Urine
Application Note: 346 MS/MS as an LC Detector for the Screening of Drugs and Their Metabolites in Race Horse Urine Gargi Choudhary and Diane Cho, Thermo Fisher Scientific, San Jose, CA Wayne Skinner and
More informationROLE OF CYTOCHROME P-4502C9 IN IRBESARTAN OXIDATION BY HUMAN LIVER MICROSOMES
0090-9556/99/2702-0288 296$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 27, No. 2 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. ROLE OF CYTOCHROME
More informationUPLC-MS/MS Analysis of Azole Antifungals in Serum for Clinical Research
Stephen Balloch and Gareth Hammond Waters Corporation, Wilmslow, UK APPLICATION BENEFITS Analytical selectivity afforded by mass selective detection Wide linear measuring range Simple, inexpensive sample
More informationIn vitro metabolism of corydaline in human liver microsomes and hepatocytes using liquid chromatography-ion trap mass spectrometry
1102 J. Sep. Sci. 2012, 35, 1102 1109 Hye Young Ji 1 Hyeri Lee 1,2 Jeong-Han Kim 2 Ki Hyun Kim 3 Kang Ro Lee 3 Hyun Joo Shim 4 Miwon Son 4 Hye Suk Lee 1 1 Drug Metabolism & Bioanalysis Laboratory, College
More informationAnalysis of anti-epileptic drugs in human serum using an Agilent Ultivo LC/TQ
Application Note Clinical Research Analysis of anti-epileptic drugs in human serum using an Agilent Ultivo LC/TQ Authors Jennifer Hitchcock 1, Lauren Frick 2, Peter Stone 1, and Vaughn Miller 2 1 Agilent
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationBritish Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2006.02627.x An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors,
More informationReevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations
0090-9556/11/3905-904 911$25.00 DRUG METABOLISM AND DISPOSITION Vol. 39, No. 5 Copyright 2011 by The American Society for Pharmacology and Experimental Therapeutics 37689/3680906 DMD 39:904 911, 2011 Printed
More informationMEDCH/PCEUT 527 ADVANCED DRUG METABOLISM 2019 Course Coordinators: Allan Rettie and Ken Thummel When/ Where:
MEDCH/PCEUT 527 ADVACED DRUG METABLISM 2019 Course Coordinators: Allan Rettie and Ken Thummel When/ Where: 2.30 4.00 pm MWF in H074 Date Topic Instructor Jan 7 Introduction Rettie/Thummel Jan 9 P450 I:
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationBIOSYNTHESIS OF ALL-TRANS-RETINOIC ACID FROM ALL-TRANS-RETINOL: CATALYSIS OF ALL-TRANS-RETINOL OXIDATION BY HUMAN P-450 CYTOCHROMES
0090-9556/00/2803-0315 322$02.00/0 DRUG METABOLISM AND DISPOSITION Vol. 28, No. 3 Copyright 2000 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. BIOSYNTHESIS OF
More informationIt the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.
It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein
More informationApplication Note. Abstract. Authors. Pharmaceutical
Analysis of xycodone and Its Metabolites-oroxycodone, xymorphone, and oroxymorphone in Plasma by LC/MS with an Agilent ZRBAX StableBond SB-C18 LC Column Application ote Pharmaceutical Authors Linda L.
More informationSupporting information
Supporting information Figure legends Supplementary Table 1. Specific product ions obtained from fragmentation of lithium adducts in the positive ion mode comparing the different positional isomers of
More informationEdgar Naegele. Abstract
Simultaneous determination of metabolic stability and identification of buspirone metabolites using multiple column fast LC/TOF mass spectrometry Application ote Edgar aegele Abstract A recent trend in
More informationSTEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES
0090-9556/03/3110-1227 1234$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 10 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1086/1095069 DMD 31:1227 1234, 2003
More informationLC/MS Method for Comprehensive Analysis of Plasma Lipids
Application Note omics LC/MS Method for Comprehensive Analysis of Plasma s Authors Tomas Cajka and Oliver Fiehn West Coast Metabolomics Center, University of California Davis, 451 Health Sciences Drive,
More informationStatin differences - Are they all the same?
Statin differences - Are they all the same? LDL Cholesterol Goals and Cutpoints (2004) Risk Category LDL Goal (mg/dl) LDL (mg/dl) - Therapeutic Lifestyle Changes LDL (mg/dl) - Drug Therapy (TLC) CHD or
More informationTHE GASTROPROKINETIC AND ANTIEMETIC DRUG METOCLOPRAMIDE IS A SUBSTRATE AND INHIBITOR OF CYTOCHROME P450 2D6
0090-9556/02/3003-336 343$3.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 3 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 500/964304 DMD 30:336 343, 2002 Printed
More informationBACKGROUND AND PURPOSE
British Journal of Pharmacology DOI:10.1111/j.1476-5381.010.00913.x www.brjpharmacol.org RESEARCH PAPER Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of
More informationA Robustness Study for the Agilent 6470 LC-MS/MS Mass Spectrometer
A Robustness Study for the Agilent 7 LC-MS/MS Mass Spectrometer Application Note Clinical Research Authors Linda Côté, Siji Joseph, Sreelakshmy Menon, and Kevin McCann Agilent Technologies, Inc. Abstract
More informationRobust extraction, separation, and quantitation of structural isomer steroids from human plasma by SPE-UHPLC-MS/MS
TECHNICAL NOTE 21882 Robust extraction, separation, and quantitation of structural isomer steroids human plasma by SPE-UHPLC-MS/MS Authors Jon Bardsley 1, Kean Woodmansey 1, and Stacy Tremintin 2 1 Thermo
More informationCharacterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
Characterization of the cytochrome P45 enzymes involved in the in vitro metabolism of rosiglitazone S. J. Baldwin, S. E. Clarke & R. J. Chenery Department of Drug Metabolism and Pharmacokinetics, SmithKline
More informationUPLC/MS Monitoring of Water-Soluble Vitamin Bs in Cell Culture Media in Minutes
UPLC/MS Monitoring of Water-Soluble Vitamin Bs in Cell Culture Media in Minutes Catalin E. Doneanu, Weibin Chen, and Jeffrey R. Mazzeo Waters Corporation, Milford, MA, U.S. A P P L I C AT ION B E N E F
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationEffects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese
et al. British Journal of Clinical Pharmacology DOI:.46/j.365-5.3.3.x Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese Ichiro Fukazawa, Naoki Uchida, Eiji Uchida
More informationCOPYRIGHTED MATERIAL IN VITRO EVALUATION OF METABOLIC DRUG DRUG INTERACTIONS: CONCEPTS AND PRACTICE ALBERT P. LI
1 IN VITRO EVALUATION OF METABOLIC DRUG DRUG INTERACTIONS: CONCEPTS AND PRACTICE ALBERT P. LI CONTENTS 1.1 Introduction 2 1.2 Mechanisms of Adverse Drug Drug Interactions 4 1.2.1 Pharmacological Interactions
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen This full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14779
More informationMETABOLISM OF ( )- AND ( )-LIMONENES TO RESPECTIVE CARVEOLS AND PERILLYL ALCOHOLS BY CYP2C9 AND CYP2C19 IN HUMAN LIVER MICROSOMES
0090-9556/02/3005-602 607$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 5 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 641/981193 DMD 30:602 607, 2002 Printed
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationTHE INTERACTIONS OF A SELECTIVE PROTEIN KINASE C BETA INHIBITOR WITH THE HUMAN CYTOCHROMES P450
0090-9556/02/3009-957 961$7.00 DRUG METABOLISM AND DISPOSITION Vol. 30, No. 9 Copyright 2002 by The American Society for Pharmacology and Experimental Therapeutics 709/1002395 DMD 30:957 961, 2002 Printed
More informationJohn Haselden 1, Gordon Dear 1, Jennifer H. Granger 2, and Robert S. Plumb 2. 1GlaxoSmithKline, Ware, UK; 2 Waters Corporation, Milford, MA, USA
Challenges of Polar Compound Analysis Routine LC/MS-based analyses usually rely on using reversed-phase column chemistries (e.g. C 18, C 8, C 4 ) in their LC methodology. However, one of the shortcomings
More informationsonidegib (LDE225) with perpetrators of CYP3A in cancer patients Heidi J. Einolf, Jocelyn Zhou, Christina Won, Lai Wang, Sam Rebello
A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients Heidi J. Einolf, Jocelyn Zhou, Christina
More informationDepartment of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai , China
Biomedicine and Biotechnology Volume 2012, Article ID 386230, 4 pages doi:10.1155/2012/386230 Research Article The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin
More informationInteractions between neuroleptics and CYP2C6 in rat liver in vitro and ex vivo study
Pharmacological Reports 2005, 57, 872 877 ISSN 1734-1140 Copyright 2005 by Institute of Pharmacology Polish Academy of Sciences Short communication Interactions between neuroleptics and CYP2C6 in rat liver
More informationUsing Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop
Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationIN VITRO METABOLISM OF TEGASEROD IN HUMAN LIVER AND INTESTINE: ASSESSMENT OF DRUG INTERACTIONS
0090-9556/01/2910-1269 1276$3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 10 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 427/929773 DMD 29:1269 1276, 2001
More information